In conclusion, the inhibition of EGFR‐mediated tumorigenesis of aggressive breast CSCs by the compound 1e in combination with a low dose of doxorubicin will effectively reduce the tumor growth in TNBCs that provide a therapeutic way forward to reduce the relapse of breast cancer. Here, EGFR is linked to neoplasm.